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Background:  Even in the DES era treatment of in-stent restenosis (ISR) is still a relatively common problem for which a satisfactory solution is yet 
to be found.
Methods:  In this prospective multicenter (10) registry 121 patients with ISR, treated with a new paclitaxel-eluting balloon (3.0μg/m2 balloon 
surface area) were included. All lesions were pre-dilated using conventional balloon angioplasty. Dual antiplatelet therapy was recommended for at 
least 1 month. The only exclusion criteria were acute STEMI and cardiogenic shock. 
Results:  34% of patients were diabetic, 48% had previous MI. 49% had ISR of DES and 56% had ISR in a small vessel. The pattern of ISR was 
focal in 54%. Angiographic success was 96%. As compared with BMS-ISR, patients with DES-ISR had adverse baseline clinical characteristics with 
more diabetes (41% vs 27%; p=ns), and dyslipidaemia (78% vs 60%; p=0.03) and worse LVEF (LVEF <50%) (50% vs 19%; p=0.003). The occurrence 
of DES-ISR tended to involve more bifurcated lesions when compare with BMS-ISR (34% vs 19%; p= 0.07). Finally, regarding response to DEB 
treatment we observed no significant differences at 1 month, but a tendency to worse later outcomes. 
Conclusion: In a real-world population, treatment of ISR with this DEB, provides excellent mid-term results, especially in ISR pattern IC (0% MACE). 
An additional finding is that patients with DES-ISR seem to have less favourable clinical and lesion characteristics and a worse response to DEB 
treatment. 
7 month 1 month (p<0.05*) 7 month (p<0.05*)
Overall population BMS-ISR DES-ISR BMS-ISR DES-ISR
Cardiac (4) 3.3 (1) 1.6 0 (1) 1.6 (3) 5.1
MI (5) 4.1 0 (1) 1.7 0 (5) 8.5*
TLR (10) 8.3 0 (1) 1.7 (4) 6.4 (6) 10.2
MACE (14) 11.6 (1) 1.6 (1) 1.7 (5) 8.1 (9) 15.3
